Pedro J. Lopez-Baldrich, Chief Legal Officer of SharkNinja, Inc. (ECHANGE:SN), completed the sale of 24,099 ordinary shares of the company on March 3, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The transactions generated proceeds of $2,775,261, with execution prices spanning $113.64 to $116.37 per share. The filing shows the disposals were carried out in a series of separate trades rather than a single block.
Transaction details in the Form 4 break the sales into four tranches. One tranche comprised 3,476 shares sold at a weighted average price of $113.64, with trade prices ranging from $113.25 to $114.12. A second tranche of 8,202 shares carried an average price of $114.75, with individual trade prices between $114.36 and $115.35. A third tranche of 12,236 shares sold at an average of $115.85, with prices varying from $115.36 to $116.34. The final reported transaction involved 185 shares sold at $116.37 each.
Following these sales, Lopez-Baldrich is recorded as directly owning 2,273 shares of SharkNinja. The filing states the sales were made pursuant to a Rule 10b-5 trading plan that Lopez-Baldrich adopted on May 29, 2025.
Market metrics cited in the filing or accompanying disclosures note a company market value of $16.2 billion, with the stock trading at a price-to-earnings ratio of 23.43 and a PEG ratio of 0.39. InvestingPro analysis referenced in the materials indicates the stock is trading near its Fair Value. At the time of the filing, the share price was reported at $114.86, a decline of 9.5% over the previous week according to InvestingPro data.
SharkNinja’s recent operating results are also referenced in the company commentary. In the fourth quarter, adjusted sales grew 17.6%, topping consensus estimates of 16.8%. Adjusted EBITDA and adjusted earnings per share also exceeded Street forecasts, outperforming by about 2% and 7%, respectively. Those results prompted analyst moves: Canaccord Genuity raised its price target on SharkNinja to $160 while maintaining a Buy rating, and Guggenheim lifted its price target to $145. Bank of America Securities reiterated its Buy rating and cited a notable uptick in domestic product sell-through as measured by Nielsen.
Separately, the filing package includes an item on Smith+Nephew. That company announced two new distribution agreements intended to expand its product portfolio. One is an exclusive U.S. distribution deal with RMR Ortho for the ATOMIC Nitinol Fixation System, aimed at strengthening its trauma and extremities offerings. The other is a distribution agreement with SI-BONE to carry the iFuse TORQ portfolio for pelvic fracture fixation procedures. Smith+Nephew described these deals as part of broader efforts to extend its reach in the medical device market.
Is SNN a bargain right now? The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for SNN plus thousands of other stocks and find your next hidden gem with massive upside.